The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

Effective management of inherited retinal diseases requires a comprehensive approach to diagnosis and treatment, according to ...

Inder Paul Singh, a glaucoma anterior segment surgeon from southeastern Wisconsin, presented his clinical experience and a ...

A new study in The New England Journal of Medicine revealed that the PRIMA brain computer interface (BCI) retinal implant helped people with advanced age-related macular degeneration regain some ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0 ...

Ottawa, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The global macular edema and macular degeneration market size was valued at USD 10.33 billion in 2024 and is predicted to hit around USD 22.51 billion by ...

1 Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan 2 Department of Ophthalmology, Oita University, Oita, Japan Purpose: We aimed to investigate the ...